Abstract

One of the defining characteristics of the malignant phenotype is the ability to evade the host immune system. Immunotherapy as a treatment modality represents a new dawn in the way we think about the treatment of a variety of malignancies. The story of immunotherapy traces its roots to its relationship with malignant melanoma. In this article, we review the intertwined history of immunotherapy and melanoma, including the early significant history, a discussion on immune mechanisms, resistance, local and systemic immunotherapeutic modalities, and speculate on possible novel future treatment options.

Original languageEnglish (US)
Pages (from-to)25-54
Number of pages30
JournalCritical Reviews in Oncology/Hematology
Volume106
DOIs
StatePublished - Oct 1 2016

Fingerprint

Immunotherapy
Melanoma
Immune System
Therapeutics
History
Phenotype
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

@article{529b4d3d9e334da2b11cf0cb791149d2,
title = "Malignant melanoma—The cradle of anti-neoplastic immunotherapy",
abstract = "One of the defining characteristics of the malignant phenotype is the ability to evade the host immune system. Immunotherapy as a treatment modality represents a new dawn in the way we think about the treatment of a variety of malignancies. The story of immunotherapy traces its roots to its relationship with malignant melanoma. In this article, we review the intertwined history of immunotherapy and melanoma, including the early significant history, a discussion on immune mechanisms, resistance, local and systemic immunotherapeutic modalities, and speculate on possible novel future treatment options.",
author = "Koller, {Kristian M.} and Wenge Wang and Todd Schell and Cozza, {Eugene M.} and Kokolus, {Kathleen M.} and Rogerio Neves and Heath Mackley and Pameijer, {Colette R.} and Anna Leung and Bryan Anderson and Mallon, {Carol A.} and Gavin Robertson and Joseph Drabick",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.critrevonc.2016.04.010",
language = "English (US)",
volume = "106",
pages = "25--54",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

Malignant melanoma—The cradle of anti-neoplastic immunotherapy. / Koller, Kristian M.; Wang, Wenge; Schell, Todd; Cozza, Eugene M.; Kokolus, Kathleen M.; Neves, Rogerio; Mackley, Heath; Pameijer, Colette R.; Leung, Anna; Anderson, Bryan; Mallon, Carol A.; Robertson, Gavin; Drabick, Joseph.

In: Critical Reviews in Oncology/Hematology, Vol. 106, 01.10.2016, p. 25-54.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Malignant melanoma—The cradle of anti-neoplastic immunotherapy

AU - Koller, Kristian M.

AU - Wang, Wenge

AU - Schell, Todd

AU - Cozza, Eugene M.

AU - Kokolus, Kathleen M.

AU - Neves, Rogerio

AU - Mackley, Heath

AU - Pameijer, Colette R.

AU - Leung, Anna

AU - Anderson, Bryan

AU - Mallon, Carol A.

AU - Robertson, Gavin

AU - Drabick, Joseph

PY - 2016/10/1

Y1 - 2016/10/1

N2 - One of the defining characteristics of the malignant phenotype is the ability to evade the host immune system. Immunotherapy as a treatment modality represents a new dawn in the way we think about the treatment of a variety of malignancies. The story of immunotherapy traces its roots to its relationship with malignant melanoma. In this article, we review the intertwined history of immunotherapy and melanoma, including the early significant history, a discussion on immune mechanisms, resistance, local and systemic immunotherapeutic modalities, and speculate on possible novel future treatment options.

AB - One of the defining characteristics of the malignant phenotype is the ability to evade the host immune system. Immunotherapy as a treatment modality represents a new dawn in the way we think about the treatment of a variety of malignancies. The story of immunotherapy traces its roots to its relationship with malignant melanoma. In this article, we review the intertwined history of immunotherapy and melanoma, including the early significant history, a discussion on immune mechanisms, resistance, local and systemic immunotherapeutic modalities, and speculate on possible novel future treatment options.

UR - http://www.scopus.com/inward/record.url?scp=84994834554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994834554&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2016.04.010

DO - 10.1016/j.critrevonc.2016.04.010

M3 - Review article

C2 - 27637351

AN - SCOPUS:84994834554

VL - 106

SP - 25

EP - 54

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -